Ruger Board Rejects Beretta's Offer, Igniting Corporate War

LUXEMBOURG – March 31, 2026 – A simmering corporate dispute in the global firearms industry has boiled over into open conflict, as the board of Sturm, Ruger & Company, Inc. formally rejected a bid by its largest shareholder, Beretta Holding S.A., to increase its investment. The move blocks a premium tender offer and sets the stage for a contentious battle for control, pitting one of America's most iconic gunmakers against a European industrial dynasty with roots stretching back to the Renaissance.

In a sharply worded letter, Beretta Holding, which already owns 9.95% of Ruger, expressed its “disappointment and surprise” at the rejection. The Luxembourg-based conglomerate had sought an exemption from Ruger’s shareholder rights plan to launch a tender offer that would have increased its stake to over 30%. The offer, priced at $44.80 per share, represented a 20% premium over the stock's recent average price, a detail Beretta has emphasized in its public statements.

Ruger's board, however, stood firm, effectively deploying a 'poison pill' defense it adopted late last year specifically to thwart such a move. The rejection now escalates the conflict from a strategic disagreement to a likely proxy war, with Beretta signaling its intent to take its case directly to Ruger’s shareholders and pursue “all legal alternatives” to challenge the incumbent board.

The 'Poison Pill' Defense

The foundation of Ruger's defense is a limited-duration shareholder rights plan adopted on October 14, 2025. This defensive measure, commonly known as a 'poison pill,' was implemented shortly after Beretta began accumulating a significant stake and publicly expressed interest in exploring “potential areas of operational and strategic collaborations.”

The plan’s terms are stark: it is designed to trigger if any single entity acquires 10% or more of Ruger’s common stock. Beretta currently sits just below this threshold at 9.95%. If the line is crossed, the plan allows all other shareholders to purchase additional shares at a steep 50% discount, a mechanism that would massively dilute the acquirer's stake and make a takeover prohibitively expensive.

Ruger’s board has defended the poison pill as a necessary tool to protect the interests of all stockholders. In their view, the plan ensures they can properly fulfill their fiduciary duties and prevents a single entity from gaining control through “open market accumulation or other coercive tactics” without paying a fair price to all investors. It provides the board, they argue, with the time and leverage needed to evaluate Beretta's intentions and explore all strategic options for maximizing long-term value.

Beretta, however, frames the defensive measure not as a shield for shareholders, but as a barrier erected by an entrenched board. By rejecting the exemption request, Beretta claims the board “has now stood in the way of its shareholders and their ability to decide for themselves” whether to accept a lucrative, premium offer.

A Premium Offer Under Scrutiny

At the heart of Beretta's public campaign is the financial appeal of its rejected offer. The proposed $44.80 per share in cash was not just a premium, but a signal that the market endorsed. Following the announcement of Beretta's intentions, Ruger's stock surged 5.3% in premarket trading on March 25, hitting its highest level of the year. Beretta’s counsel has pointed to this as clear evidence of what shareholders desire.

To bolster its case, Beretta has launched a blistering critique of Ruger's recent financial performance. In a letter dispatched to Ruger shareholders on March 19, the European firm argued for an “urgent need for Boardroom change,” accusing Ruger of destroying shareholder value through weak execution. Beretta’s analysis claims that since 2021, Ruger has significantly underperformed its competitors and relevant market indexes, citing a dramatic deterioration in key financial metrics. According to Beretta, Ruger’s gross margin has plummeted from 38% to 15%, its operating margin has swung from a healthy 28% to a negative 2%, and a net income of $156 million has turned into a $4.4 million loss.

From Beretta’s perspective, its premium offer is not just generous, but a necessary lifeline for a company whose leadership has failed to capitalize on favorable industry conditions. Ruger’s board is now under pressure to justify why turning down a 20% premium is in the best long-term interest of the shareholders it is sworn to protect, especially in the face of such pointed financial criticism.

The Looming Battle for the Boardroom

With the financial path blocked, the conflict is now shifting to the corporate governance arena. Beretta has made its next move clear: it intends to file a preliminary proxy statement and nominate its own slate of “highly qualified” directors for election at Ruger’s 2026 annual meeting of stockholders.

This signals the beginning of a proxy fight, a costly and often acrimonious campaign to win the votes of shareholders and replace the incumbent board. Beretta’s slate of nominees includes experienced figures such as William F. Detwiler, Mark DeYoung, Fredrick DiSanto, and Michael Christodolou, who will be presented as the agents of change needed to reverse Ruger’s fortunes.

Ruger’s leadership appears to be preparing for this very fight. The company recently launched a dedicated shareholder website to make its case, highlighting its own narrative of capital stewardship, shareholder returns, and strategic direction. The board has also emphasized its own recent refreshment, which has seen five new directors join its ranks, an apparent move to preemptively counter claims of being stale or entrenched.

Both sides are now engaged in a public relations and investor relations war, vying for the support of the institutional investors and retail shareholders who will ultimately decide the company's fate. The central question they will vote on is whether Ruger’s current path is sound or if the company would be better served by the strategic influence and operational input of its largest, and now most adversarial, shareholder.

Two Titans at a Crossroads

This confrontation represents a pivotal moment for both companies. Ruger, a pillar of the American firearms market, faces a challenge to its independence. An increased stake or board representation for Beretta could fundamentally alter Ruger's strategic direction, product development, and brand identity. Beretta Holding, with a portfolio of over 20 internationally recognized brands like Benelli, Sako, and Burris Optics, operates as a global empire, and integration into its orbit could bring both opportunities for synergy and risks of cultural clashes.

Beretta maintains that its goal is to “partner with the Company in order to improve performance and deliver sustainable long-term value for all stockholders, employees and customers.” However, the incumbent board's resistance suggests a deep skepticism about Beretta's true intentions and the potential disruption that a change in control or influence could bring.

As both sides prepare their legal and strategic arsenals, a meeting between the principals of Beretta and Ruger has been scheduled for April 9. Whether this meeting can produce a “constructive resolution” or will simply be a prelude to further hostilities remains to be seen. With legal action threatened and a proxy battle all but declared, the future of Sturm, Ruger & Company will likely be decided not in a quiet boardroom, but in a public showdown for the hearts and minds of its shareholders.